Skip to Main Content

Paper Details

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Leukemia
147
2019
CK, CK-, CK-MDS, MDS, Monosomal, NRAS, NRAS mutation, SF3B1, SF3B1 mutation, TP53, TP53 mutation, TP53 mutations, anemia, blast, chromosomal, chromosomal abnormality, co-mutated genes, cytogenetic abnormalities, del(5q), hemoglobin, monosomy 7, myelodysplastic syndromes, patients
Author NameAffiliation
Donna NeubergDana-Farber Cancer Institute
Benjamin L EbertDana-Farber Cancer Institute
Guillermo Garcia-ManeroUniversity of Texas MD Anderson Cancer Center
Torsten Haferlach
Torsten HaferlachCleveland Clinic Taussig Cancer Center
Timothy A GraubertMassachusetts General Hospital Cancer Center
Matthew J WalterWashington University School of Medicine
Peter J CampbellWellcome Trust Sanger Institute
Lionel Ad??sAssistance Publique-Hopitaux de Paris and Paris Diderot University
David P SteensmaDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
Michael HeuserHannover Medical School
Felicitas TholHannover Medical School
Luca MalcovatiFondazione IRCCS Policlinico San Matteo & University of Pavia
Rafael Bejaruniversity of california san diego Moores Cancer Center
  • 1 - 15

Datasets

Release 1.2